This article first appeared on GuruFocus.

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $3.33 million, and the earnings are expected to come in at -$0.79 per share. The full year 2025's revenue is expected to be $36.64 million and the earnings are expected to be -$3.07 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 6 Warning Signs with EYPT.

Is EYPT fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) have declined from $40.38 million to $36.64 million for the full year 2025 and declined from $19.50 million to $15.94 million for 2026 over the past 90 days. Earnings estimates have declined from -$3.04 per share to -$3.07 per share for the full year 2025 and increased from -$2.93 per share to -$2.92 per share for 2026 over the past 90 days.

In the previous quarter of 2025-06-30, EyePoint Pharmaceuticals Inc's (NASDAQ:EYPT) actual revenue was $5.33 million, which missed analysts' revenue expectations of $6.63 million by -19.53%. EyePoint Pharmaceuticals Inc's (NASDAQ:EYPT) actual earnings were -$0.85 per share, which missed analysts' earnings expectations of -$0.82 per share by -4.29%. After releasing the results, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) was down by -2.85% in one day.

Based on the one-year price targets offered by 12 analysts, the average target price for EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) is $34.42 with a high estimate of $68.00 and a low estimate of $23.00. The average target implies an upside of 176.88% from the current price of $12.43.

Based on GuruFocus estimates, the estimated GF Value for EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) in one year is $2.04, suggesting a downside of -83.59% from the current price of $12.43.

Based on the consensus recommendation from 13 brokerage firms, EyePoint Pharmaceuticals Inc's (NASDAQ:EYPT) average brokerage recommendation is currently 1.70, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.